Corey J. Langer, MD

Articles

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC

August 11th 2023

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Dr. Langer on the Benefit of Atezolizumab Following Progression in Advanced NSCLC

September 1st 2022

Corey J. Langer, MD, discusses the benefit observed with the continued treatment of atezolizumab following disease progression in patients with advanced non–small cell lung cancer.

Dr. Langer on the Evolution of Molecular Testing in Advanced NSCLC

November 15th 2021

Corey J. Langer, MD, professor of medicine, University of Pennsylvania, director, Thoracic Oncology, Penn Medicine, discusses the evolution of molecular testing in advanced non–small cell lung cancer.

Dr. Langer on the Need for Reflex Testing in NSCLC

November 10th 2021

Corey J. Langer, MD, discusses the need for reflex testing in patients with non–small cell lung cancer.

Dr. Langer on the Future of Immunotherapy for Treatment of NSCLC

September 10th 2019

Corey J. Langer, MD, director, thoracic oncology, Penn Medicine, discusses the future of immunotherapy during a discussion about KEYNOTE-021 at the 2019 World Conference on Lung Cancer.

Dr. Langer on the Current State of Immunotherapy in Advanced NSCLC

June 20th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the current state of immunotherapy in advanced non–small cell lung cancer.

Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC

May 29th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of durvalumab in stage III non–small cell lung cancer.

Dr. Langer Discusses the Use of NGS in NSCLC

May 23rd 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the use of next-generation sequencing in non–small cell lung cancer.

Dr. Langer Discusses the Impact of Targeted Therapy in NSCLC

May 15th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.

Dr. Langer on the Impact of the PACIFIC Trial on Stage III NSCLC

September 5th 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the PACIFIC trial results on the treatment landscape of stage III non–small cell lung cancer.

Dr. Langer on the Impact of Frontline Immunotherapy in Lung Cancer

August 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

July 27th 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.

Dr. Langer on the IMpower150 Trial in NSCLC

July 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of the IMpower150 trial in patients with non–small cell lung cancer (NSCLC).

Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer

January 5th 2015

Corey Langer, MD, the director of Thoracic Oncology at the University of Pennsylvania, discuses afatinib, which was approved in 2013 for first line EGFR-mutated advanced non-small cell lung cancer.

Dr. Langer on the Treatment of Early Stage Lung Cancer

October 8th 2013

Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.

Dr. Langer Discusses Afatinib in EGFR-Positive NSCLC

August 13th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses integrating the irreversible pan-HER inhibitor afatinib into the treatment paradigm for patients with advanced non-small cell lung cancer.

Dr. Corey Langer Discusses Erlotinib in Advanced NSCLC

January 15th 2013

Corey J. Langer, MD, from the University of Pennsylvania, Abramson Cancer Center, discusses the EGFR-targeted tyrosine kinase inhibitor erlotinib for patients with non-small cell lung cancer.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Dr. Langer Discusses Treating Locally Advanced NSCLC

August 29th 2012

Dr. Corey Langer, from the University of Pennsylvania, Abramson Cancer Center, Discusses Treating Locally Advanced Non-small Cell Lung Cancer.

Dr. Langer Discusses the PARAMOUNT Study

November 2nd 2011

Dr. Corey Langer from the Abramson Cancer Center Discusses the PARAMOUNT Study

NEXT PAGE
PREVIOUS PAGE